Author: Ravi Shankar

Expands Customer Engagement and Support Capabilities Across North America

Supports Growing Demand Across Leading Aerospace and Defense Customers

Provides Access to Advanced Manufacturing Solutions, Application Development and Process Evaluation

WALTHAM, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) — Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension,” “Nano”, or the “Company”) today announced that its Essemtec business unit has relocated its U.S. headquarters to a new facility in Woburn, Massachusetts, reinforcing its established presence in the United States and supporting its continued business growth.

The relocation comes amid strong operating momentum at Essemtec, with accelerating revenue growth, expanding customer relationships and demand for its advanced electronics manufacturing solutions.

Essemtec has developed a significant presence in the aerospace and defense industries, serving leading customers with demanding requirements for precision, reliability, and manufacturing performance. The business also engages with leading global electronics manufacturing services companies serving large-scale customers, including in AI-related manufacturing applications, and has expanded deployments with leading space and satellite companies.

Accelerating Growth and Strong Market Position

Essemtec continues to deliver strong business performance, supported by growing demand across its core markets, particularly aerospace and defense.

The new U.S. headquarters strengthens customer engagement and provides customers across North America with access to equipment demonstrations, application development, and process evaluation, supporting Essemtec’s established position in the North American market and its continued growth opportunities.

Moshe Rozenbaum, Interim Chief Executive Officer of Nano Dimension, commented, “Essemtec is performing exceptionally well. We are seeing accelerating revenue growth, strong commercial momentum, and increasing demand from leading customers in the aerospace and defense industries. The quality of Essemtec’s customer base is a testament to the strength of its technology and its ability to meet the demanding standards of these industries. The new U.S. headquarters reflects our confidence in the business and its growth opportunities, strengthening our ability to support customers and build on Essemtec’s commercial momentum. We believe Essemtec is well positioned to continue delivering strong operating performance and creating value for our shareholders.”

About Essemtec

Essemtec is renowned for its adaptive, highly flexible SMT pick-and-place equipment, sophisticated dispensers suitable for both high-speed and micro-dispensing, and intelligent production material storage and logistic systems. All products are equipped with advanced software packages, ensuring efficient material management and user-friendly operation. Essemtec’s solutions are implemented worldwide across various industries, reflecting the company’s commitment to quality and innovation.

About Nano Dimension Ltd.

Nano Dimension Ltd. (Nasdaq: NNDM) has historically delivered advanced digital manufacturing technologies, including serving customers across the defense, aerospace, automotive, electronics and medical device industry segments. For more information, please visit www.nano-di.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include expectations regarding Essemtec’s future revenue growth, commercial momentum, customer demand and operating performance; its growth opportunities and market position, including in the aerospace and defense industries; the anticipated benefits of its new U.S. headquarters, including enhanced customer engagement, application development, process evaluation and customer support; and its ability to create shareholder value. Statements other than statements of historical fact may be forward-looking. Forward-looking statements may be identified by words such as “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “may,” “could,” “will,” “continue,” and similar expressions, although not all forward-looking statements contain these words.

These statements reflect management’s current expectations, beliefs and assumptions and are not guarantees of future performance. Actual results could differ materially due to risks and uncertainties, including changes in customer demand and capital spending, particularly in the aerospace, defense and electronics manufacturing markets; delays, reductions or cancellations in customer orders; competition and technological developments; supply-chain disruptions and changes in component availability or costs; changes in tariffs, trade restrictions and economic conditions; and Essemtec’s ability to realize the anticipated operational and commercial benefits of the new facility. Additional risks and uncertainties are described under “Risk Factors” in Nano Dimension’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission on March 31, 2026, and in subsequent SEC filings.

Forward-looking statements speak only as of the date of this press release. Except as required by applicable law, Nano Dimension undertakes no obligation to update or revise them, whether as a result of new information, future events or otherwise. References and links to websites are provided for convenience; information on those websites is not incorporated by reference into this press release.

Contacts:

Investors:
Purva Sanariya
Director, Investor Relations
ir@nano-di.com

Media:
Samuel Manning
Principal Manager, External Communications
press@nano-di.com

STMicroelectronics announces status
of common share repurchase program

Disclosure of Transactions in Own Shares – Period from October 19, 2026 to October 23, 2026

AMSTERDAM – October 26, 2026 — STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global semiconductor leader serving customers across the spectrum of electronics applications, announces full details of its common share repurchase program (the “Program”) disclosed via a press release dated June 21, 2024. The Program was approved by a shareholder resolution dated May 22, 2024 and by the supervisory board.

STMicroelectronics N.V. (registered with the trade register under number 33194537) (LEI: 213800Z8NOHIKRI42W10) announces the repurchase (by a broker acting for the Company) on the regulated market of Euronext Paris, in the period between October 19, 2026 to October 23, 2026 (the “Period”), of 444,659 ordinary shares (equal to 0.05% of its issued share capital) at the weighted average purchase price per share of EUR 40.5207 and for an overall price of EUR    18,017,915.91.

The purpose of these transactions under article 5(2) of Regulation (EU) 596/2014 (the Market Abuse Regulation) was to meet obligations arising from share option programmes, or other allocations of shares, to employees or to members of the administrative, management or supervisory bodies of the issuer or of an associate company.

The shares may be held in treasury prior to being used for such purpose and, to the extent that they are not ultimately needed for such purpose, they may be used for any other lawful purpose under article 5(2) of the Market Abuse Regulation.

Below is a summary of the repurchase transactions made in the course of the Period in relation to the ordinary shares of STMicroelectronics (ISIN: NL0000226223), in detailed form.

  

Transactions in Period

Dates of transaction	Number of shares purchased	Weighted average purchase price per share (EUR)	Total amount paid (EUR)	Market on which the shares were bought (MIC code)
19-Oct-26	80,000	41.1554	3,292,432.00	XPAR
20-Oct-26	89,843	40.2403	3,615,309.27	XPAR
21-Oct-26	80,000	41.7299	3,338,392.00	XPAR
22-Oct-26	106,766	40.4155	4,315,001.27	XPAR
23-Oct-26	88,050	39.2593	3,456,781.37	XPAR
Total for Period	444,659	40.5207	18,017,915.91

Following the share buybacks detailed above, the Company holds in total 16,867,047 treasury shares, which represents approximately 1.9% of the Company’s issued share capital.

In accordance with Article 5(1)(b) of the Market Abuse Regulation and Article 2(3) of Commission Delegated Regulation (EU) 2016/1052, a full breakdown of the individual trades in the Program are disclosed on the ST website (https://investors.st.com/stock-and-bond-information/share-buyback).

About STMicroelectronics
At ST, we are 49,000 creators and makers of semiconductor technologies mastering the semiconductor supply chain with state-of-the-art manufacturing facilities. An integrated device manufacturer, we work with more than 200,000 customers and thousands of partners to design and build products, solutions, and ecosystems that address their challenges and opportunities, and the need to support a more sustainable world. Our technologies enable smarter mobility, more efficient power and energy management, and the wide-scale deployment of cloud-connected autonomous things. We are on track to be carbon neutral in all direct and indirect emissions (scopes 1 and 2), product transportation, business travel, and employee commuting emissions (our scope 3 focus), and to achieve our 100% renewable electricity sourcing goal by the end of 2027. Further information can be found at www.st.com   

For more information, please contact:

INVESTOR RELATIONS
Jérôme Ramel
EVP Corporate Development & Integrated External Communication
Tel: +41.22.929.59.20
jerome.ramel@st.com    
  
MEDIA RELATIONS
Alexis Breton
Group VP Corporate External Communications
Tel: +33.6.59.16.79.08
alexis.breton@st.com

Attachment

• C3418C — Oct 26 2026 — Disclosure of transactions in Own Shares PR_FINAL FOR PUBLICATION

Durability of faridoxorubicin (AVA6000) activity results from the continued release of doxorubicin by fibroblast activation protein (FAP) demonstrated beyond 10 cycles of therapy

FAPI-PET imaging data indicate prolonged expression of FAP despite deep tumor responses in multiple patients

LONDON and PHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) — Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a life sciences company developing innovative, targeted oncology drugs, today announces the presentation of updated data from the ongoing Phase 1a/1b trial of faridoxorubicin (AVA6000) reporting a median progression-free survival (PFS) of 11.4 months in a defined subset of patients with salivary gland cancer (SGC), compared with published historical benchmarks of 6-6.7 months. Meaningful tumor shrinkage was also observed in the patient population.

In the SGC efficacy subset (n=32), the observed median PFS of 11.4 months (95% confidence interval (CI): 7 months, not reached), represents a near doubling compared with historical benchmarks. These benchmarks are based on multiple studies of both cytotoxic regimens and targeted therapy in the earlier lines of therapy, expected to be most similar to the SGC efficacy subset (reviewed in Kanno, et al. 2025).

FAP inhibitor-positron emission tomography (FAPI-PET) imaging data and corresponding pharmacokinetic (PK) data indicate sustained FAP expression over time in patients that is associated with prolonged release of doxorubicin beyond 10 cycles of therapy. Recent preclinical platform data suggest this persistent release of payload is due to the recruitment of FAP+ fibroblasts to the tumor over the course of pre|CISION^® therapy.

Faridoxorubicin is the Company’s first-generation pre|CISION^® peptide-drug conjugate (PDC) delivering a doxorubicin payload directly to the tumor. Data from the trial in patients with FAP-positive solid tumors are being presented at the European Society for Medical Oncology (ESMO) Congress in Madrid, held between 23-27 October 2026.

Christina Coughlin, CEO of Avacta, commented:

“Our two datasets presented at ESMO demonstrate that our pre|CISION^® platform is capable of delivering highly potent payloads to tumors over prolonged periods with sustained antitumor activity observed in patients and preclinical models. This activity occurs without the toxicity that limits the effectiveness of antibody-drug conjugates (ADCs) and their payloads, significantly widening the therapeutic index. Our first significant PFS results showing clinically meaningful progression-free intervals and tumor shrinkage in many patients support that the pre|CISION^® platform can significantly improve outcomes for patients with cancer with the necessary durability.

“Importantly, new preclinical data presented at ESMO on Friday with FAP-Exd (AVA6103), the Company’s first Next-Generation pre|CISION^® controlled-release PDC, demonstrate the mechanism of these findings, namely that treated tumors recruit new FAP+ fibroblasts, enhancing the capacity of the tumor to continue to cleave the pre|CISION medicines over time.  

“This is further evidence that the effect of pre|CISION^® PDCs can persist even as tumors shrink, an exciting differentiator compared with ADCs and first-generation PDCs, where antigen loss is thought to contribute to the question of durability. We look forward to presenting data on tumor pharmacokinetics (PK) and durability of cleavage for our lead candidate AVA6103 in late 2026 and the first efficacy data in H1 2027.”

Alan Ho, MD, PhD, Chief, Head and Neck Oncology Service, Memorial Sloan Kettering Cancer Center, New York and Senior Author of the ESMO Presentation commented,

“These are promising results with faridoxorubicin in patients with salivary gland cancers, highlighted by evidence of disease control in this rare set of diseases for which effective therapies are lacking. Evidence of enhanced FAP expression in the FAPI-PET data is unique pharmacodynamic data.”

Phase 1a/1b Trial of Faridoxorubicin (AVA6000)

The faridoxorubicin (AVA6000) Phase 1a dose escalation enrolled patients with a diagnosis of cancers frequently noted as FAP-positive. Three indications were selected for the Phase 1b expansion: SGC, soft tissue sarcoma (STS), and triple-negative breast cancer (TNBC). Data sets for STS and TNBC continue to mature.

Endpoints include safety, PK and preliminary efficacy. AVA6000 is administered as an infusion every three weeks (Q3W) or every two weeks (Q2W). A total of 51 patients with SGC were enrolled across all doses and cohorts, with any prior therapy. In the reported set of 32 patients with SGC treated at doses of 310 mg/m² and above, patients with rare histologies and more extensive prior therapy were excluded from this analysis set. The data cutoff reported here was October 5, 2026.

• Faridoxorubicin (AVA6000) was well-tolerated in this set of patients with SGC (n=32) and resulted in prolonged median PFS of 11.4 months (95% CI: 7 months, not reached), exceeding benchmarks in the 1L and 2L setting by nearly two-fold across both cytotoxic chemotherapy and targeted therapy (median 6-6.7 months, Kanno et al. 2025). Median OS in this population has not been reached.
• Multiple partial (n=3) and minor responses (n=6) were observed in the reported SGC dataset with a range of duration (18.7-72 weeks).
• Biopsy data show a significant concentration of tumor to plasma of released doxorubicin of 100:1, resulting in tumor reductions even at low levels of FAP expression (1+).
• FAPI-PET imaging and FAP IHC data indicate that FAP expression in tumors does not diminish over time during treatment with faridoxorubicin in multiple tumor types even in the setting of tumor response
• Plasma PK studies out to 12 cycles of therapy show that cleavage of faridoxorubicin to peptide and doxorubicin by FAP is stable over time, indicating persistent FAP activity
  in tumors.

Details of the ESMO presentation

A Phase 1a/1b trial of FAP-Dox (AVA6000), a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with salivary gland cancers  

Authors: Renata Ferrarotto, Robert Metcalf, Steph A. Pang, William D. Tap, et. al, Alan L. Ho      
Poster number: 1549P
Time: Monday October 26, 12:00-12:45pm CET

The poster can be found on Avacta’s website here.

Kanno M, et al. Palliative systemic therapy for locally advanced or metastatic salivary duct carcinoma: A comprehensive review. Cancer Treat Rev. 2025;139:102993. doi: 10.1016/j.ctrv.2025.102993

Dr. Ho has financial interests related to Avacta Therapeutics.

Enhertu^® (trastuzumab deruxtecan; T-DXd) is a protease cleavable-linker ADC, approved for both breast cancer and gastric cancer indications (an AstraZeneca/Daiichi Sankyo product). Enhertu^® is a registered trademark of Daiichi Sankyo Company, Limited and AstraZeneca.

For further information from Avacta, please contact:

Avacta Group plc Christina Coughlin, Chief Executive Officer	https://avacta.com/ via Cohesion Bureau
Strand Hanson Limited (Nominated Adviser) James Harris / Chris Raggett / James Dance	www.strandhanson.co.uk
Zeus (Broker) James Hornigold / George Duxberry (Investment Banking)   Dominic King / Alex Bartram (Corporate Broking)	www.zeuscapital.co.uk
Cohesion Bureau Communications / Media / Investors Chris Maggos	avacta@cohesionbureau.com

About Avacta – https://avacta.com/

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies through its proprietary pre|CISION® platform. pre|CISION® is a payload delivery system based on a tumor-specific protease (Fibroblast Activation Protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Avacta’s innovative pre|CISION® peptide drug conjugates (PDC) are a novel entry to the XDC drug class, leveraging the success of antibody drug conjugates with alternative methods of delivery beyond antibodies.

Our pre|CISION® PDCs leverage this tumor-specific release mechanism in a small molecule format to provide unique benefits over traditional antibody drug conjugates (ADC), releasing active payload in the tumor and reducing systemic exposure and toxicity which enables dosing to be optimized to deliver the best outcomes for patients. The lead clinical program is AVA6103, a Next Generation FAP-enabled controlled release pre|CISION® version of exatecan that delivers the payload directly in the tumor with limited peripheral blood exposure and is currently in clinical development as a treatment for tumor types sensitive to exatecan including cervical cancer, HR+ breast cancer, small cell lung cancer, gastric cancer, colorectal cancer and pancreatic cancer.

About FAP-Exd (AVA6103)

AVA6103 is the second clinical candidate and is the first asset in the pipeline based on the Next Generation innovative pre|CISION^® controlled release mechanism that provides for prolonged release of payload directly in the tumor, minimizing systemic exposure. AVA6103 is being evaluated in the FOCUS-01 Phase 1 trial (FAP-Exd in Oncologic Cancers with Unmet needS). Preclinical data suggest this approach has optimized payload delivery with a high intratumoral concentration and prolonged exposure of released payload in the tumor, coupled with limited systemic exposure to the released payload. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Ramp-up completed well ahead of the six-to-eight-week timeline and the end-of-December target

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) — Namib Minerals (“Namib” or “the Company”) (Nasdaq: NAMM), today announced that the expanded milling plant at How Mine has been commissioned and is now operating at its full rate of approximately 55,000 tonnes per month.

As disclosed in the Company’s first-half 2026 results on October 1, 2026, commissioning was expected in mid-October, followed by a ramp-up of approximately six to eight weeks, with the plant expected to reach its full rate by the end of December 2026.

The plant has reached that rate well ahead of this timeline. “Reaching full capacity this quickly is a credit to the How Mine team, who delivered the expansion safely and ahead of plan reflecting the teams continued operational excellence” said CEO Tulani Sikwila.

The expansion lifts How Mine’s processing capacity from approximately 40,500 tonnes per month to approximately 55,000 tonnes per month, an increase of approximately 36%. The additional capacity is expected to alleviate the milling constraint that has limited How Mine’s throughput and is expected to enable the Company to spread its existing cost base across greater production volumes. The strengthening of How Mine’s operating platform going into Q1 of 2027 allows the team to focus on maintaining plant performance which supports stronger sustainable production and cash generation.

The Company expects to provide formal 2027 production and cost guidance, including Redwing Mine’s anticipated contribution, in Q1 2027.

About Namib Minerals

Namib Minerals (NASDAQ: NAMM) is a gold producer, developer and explorer with operations focused in Zimbabwe. Currently Namib Minerals operates the How Mine, an underground gold mine in Zimbabwe, and aims to restart two assets in Zimbabwe. For additional information, please visit namibminerals.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding the restarts of mines, future financing or other future events or circumstances, including any underlying assumptions,. Forward-looking statements are typically identified by words such as “expects,” “intends,” “plans,” “targets,” “anticipates,” “believes,” “will,” “may” and similar expressions.

These statements are based on management’s current expectations and assumptions and are subject to significant risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those expressed or implied.

Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. No assurance can be given that the Proposed Facility will be completed or funded, or that the development milestones, funding or production targets described in this press release will be achieved within the expected timeframes, or at all.

Contact:

Ira M. Gostin
Investor Relations:
Investor.relations@namibminerals.com

ASML reports transactions under its current share buyback program

VELDHOVEN, the Netherlands – ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML’s current share buyback program.

Date	Total repurchased shares	Weighted average price	Total repurchased value
19-Oct-26	67,063	€1,490.58	€99,963,082
20-Oct-26	68,250	€1,454.77	€99,288,196
21-Oct-26	67,400	€1,484.35	€100,045,473
22-Oct-26	69,297	€1,443.34	€100,019,312
23-Oct-26	71,300	€1,401.89	€99,954,714

ASML’s current share buyback program was announced on 28 January 2026. Further details are available on our website.

This regular update of the transactions conducted under the buyback program is to be made public under the Market Abuse Regulation (Nr. 596/2014).

About ASML

ASML is a leading supplier to the semiconductor industry. The company provides chipmakers with hardware, software and services to mass produce the patterns of integrated circuits (microchips). Together with its partners, ASML drives the advancement of more affordable, more powerful, more energy-efficient microchips. ASML enables groundbreaking technology to solve some of humanity’s toughest challenges, such as in healthcare, energy use and conservation, mobility and agriculture. ASML is a multinational company headquartered in Veldhoven, the Netherlands, with offices across EMEA, the US and Asia. Every day, ASML’s more than 44,100 employees (FTE) challenge the status quo and push technology to new limits. ASML is traded on Euronext Amsterdam and NASDAQ under the symbol ASML. Discover ASML – our products, technology and career opportunities – at www.asml.com.

Media Relations contacts Monique Mols, phone +31 6 528 444 18

Investor Relations contacts Jim Kavanagh, phone +31 40 268 3938 Pete Convertito, phone +1 203 919 1714 Peter Cheang, phone +886 3 659 6771

        

On 2 January 2026, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 59 of 18 December 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 240 million during the period 2 January to 31 December 2026. As outlined in Company Announcement no. 48 of 14 August 2026, the programme was extended with up to DKK 170 million, increasing the total amount of which Schouw & Co. will acquire shares to up to DKK 410 million.

The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).

Trading day	No. of shares	Average price	Amount DKK
Accumulated until 16 October 2026	538,441	718.71	386,981,306
Monday, 19 October 2026	5,000	836.52	4,182,575
Tuesday, 20 October 2026	1,793	839.29	1,504,843
Wednesday, 21 October 2026	5,000	847.73	4,238,639
Thursday, 22 October 2026	5,000	844.66	4,223,322
Friday, 23 October 2026	2,307	838.71	1,934,895
In the period 19 October 2026 – 23 October 2026	19,100	842.11	16,084,274
Accumulated until 23 October 2026	557,541	722.93	403,065,580
Following the above transactions, Schouw & Co. holds a total of 2,855,334 treasury shares corresponding to 11.42% of the total share capital of 25,000,000 shares.

Aktieselskabet Schouw & Co.

Jørgen Dencker Wisborg, Chairman
Jens Bjerg Sørensen, President, telephone number +45 86 11 22 22

Attachments

• 2026-10-26 FBM26-64 SBB-w43 ENG
• SBB2026 Week 43

POWAY, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) — Disguise, Inc., a global leader in the costume industry and a subsidiary of JAKKS Pacific, Inc. (NASDAQ: JAKK), is debuting another beloved Mushroom Kingdom character this Halloween with the debut of an all-new collection of Yoshi costumes. The new assortment gives Super Mario fans of all ages an exciting new way to celebrate the iconic character.

The new Yoshi costumes join a collection of perennial favorites including Mario, Luigi, Princess Peach, Bowser and Rosalina.

The new Yoshi collection from Disguise delivers fun, playful costume designs made for fans of all ages. Kids can imagine themselves as their favorite Super Mario character for Halloween and with a variety of choices, entire families can enjoy the experience of being part of the Mushroom Kingdom. Disguise is seeing that enthusiasm translate directly into dress-up, with families and fans embracing an increasingly broad range of characters.

Since Disguise first launched its costume collection with Nintendo in 2013, the partnership has continued to expand its assortment and reach, establishing Nintendo as one of the company’s leading brand portfolios. Today, the costumes are sold across North America, EMEA, Latin America and Australia, with fans dressing as their favorite characters not only for Halloween, but also for moviegoing, conventions, gaming events and other celebrations throughout the year.

“We are excited to give fans a fresh way to celebrate Yoshi this Halloween,” said Tara Cortner, President and GM of Disguise. “The excitement across the entire Super Mario franchise has been consistently increasing, and we’re seeing that translate into growing interest in characters beyond Mario and Luigi. From Yoshi, Bowser and Rosalina to Mario, Luigi and Princess Peach, fans are embracing the full Super Mario universe through dress-up. We’re thrilled to continue bringing these iconic characters to life as we expand our long-standing partnership with Nintendo, including iconic franchises such as The Legend of Zedla, Donkey Kong, Kirby, and Pikmin.”

Yoshi costumes are available now on Amazon in North America and EMEA, as well as Target, Walmart US and Canada, Meijer and Halloweencostumes.com.

About JAKKS Pacific, Inc.:

JAKKS Pacific, Inc. is a leading designer, manufacturer and marketer of toys and consumer products sold throughout the world, with its headquarters in Santa Monica, California. JAKKS Pacific’s popular proprietary brands include Disguise®, Fly Wheels®, Charming™, Kidtopia™, Moose Mountain®, Maui®, ReDo® Skateboard Co., Sky Ball® and Xtreme Power Dozer®, as well as a wide range of entertainment-inspired products featuring premier licensed properties. Through their products and charitable donations, JAKKS is helping to make a positive impact on the lives of children. Visit us at www.jakks.com and follow us on Instagram (@jakkspacific.toys), X (@jakkstoys), YouTube (@JAKKSPacific), Facebook (@jakkspacific.toys) and LinkedIn (JAKKS Pacific).

About Disguise Inc.

Since 1987, Disguise Inc. has been a global leader in the dress-up and costume industry, known for creating innovative, trend-setting costumes and accessories. Headquartered near San Diego, Disguise designs and manufactures millions of costumes annually, delivering joy and unforgettable memories to kids and adults alike. Disguise partners with many of the world’s most popular licensed brands and also offers an array of original, proprietary designs. Its products are distributed through major retailers, specialty shops, party stores, and seasonal pop-ups around the globe. To explore Disguise’s extensive licensed costume collection, visit www.disguise.com, and follow along on Instagram @disguise.costumes, X (formerly Twitter) @DisguiseInc, and Facebook Disguise Costumes.

MEDIA CONTACT:

PR@Disguise.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/099a8c87-e270-4b0b-a0be-db9a72f49ce7

Company initiates hardware experiments intended to integrate quantum processor characterization, circuit execution and decoding into a unified workflow, marking a key milestone in its development efforts toward real-time quantum error correction

TEL AVIV, Israel, Oct. 26, 2026 (GLOBE NEWSWIRE) — Quantum X Labs Inc. (NASDAQ: QXL) (“Quantum X Labs” or the “Company”), a quantum technology company developing advanced solutions across quantum computing, quantum error correction, quantum software, cybersecurity and quantum sensing, today announced the launch of its end-to-end Quantum Error Correction (QEC) program on the Arbel superconducting quantum processor at the Israeli Quantum Computing Center (IQCC), operated by Quantum Machines.

The Company believes the program represents an important technological milestone in its efforts to develop an integrated quantum error correction architecture designed to improve the reliability and scalability of quantum computing systems.

Quantum X Labs has initiated its first hardware experiments on the Arbel processor, establishing the foundation for a unified workflow that connects quantum device characterization, circuit execution and error decoding. By bringing these capabilities together on actual quantum computing hardware, the Company aims to advance beyond isolated error correction components toward a comprehensive system capable of identifying, processing and correcting quantum errors within a coordinated operational framework.

Quantum error correction is widely regarded as one of the critical technological challenges facing the quantum computing industry. Quantum processors are inherently sensitive to environmental interference, imperfect operations and other sources of noise that can introduce errors during computations. Overcoming these limitations is essential to the development of reliable, fault-tolerant quantum computers capable of executing increasingly complex algorithms.

Quantum X Labs’ program is designed to address this challenge through an integrated architecture connecting three essential technological layers:

Quantum Device Characterization and Calibration: Analyzing processor behavior, identifying hardware-specific noise characteristics and generating information that can support improved quantum operations.

Quantum Control and Circuit Execution: Integrating characterization data into the execution and control workflow to support more effective operation of quantum circuits on physical hardware.

Noise-Aware Quantum Error Decoding: Applying the Company’s developing quantum error correction decoder to interpret error information and identify appropriate corrections, with the objective of ultimately supporting real-time operation.

The initial experiments on the Arbel superconducting processor establish the hardware foundation for this architecture, with the next phase focused on incorporating the Company’s noise-aware decoder directly into the operational workflow.

The Company intends to develop its end-to-end quantum error correction workflow in collaboration with control-system and accelerated-computing partners, with the objective of connecting quantum hardware operations and classical computational processing into a coordinated system.

This approach is intended to address one of the fundamental requirements of fault-tolerant quantum computing: the ability to process error information rapidly enough to support quantum operations as they occur.

The Company’s development roadmap calls for progressively integrating processor characterization, quantum control and accelerated decoding capabilities, ultimately targeting a closed-loop architecture in which error information generated by the quantum processor can be analyzed and translated into corrective actions with minimal latency.

Quantum X Labs believes that quantum error correction will play an increasingly important role as the industry transitions from experimental quantum processors toward larger, more reliable and commercially useful quantum computing systems.

Rather than developing decoding algorithms solely through theoretical models and simulations, the Company’s approach emphasizes validation and integration with real quantum hardware, enabling its technologies to be evaluated against the operational characteristics and noise profiles of physical quantum processors.

The program also reflects Quantum X Labs’ broader strategy of developing technologies that can operate across different quantum computing architectures, combining quantum software, advanced algorithms, error correction and classical accelerated computing to support the emerging quantum computing ecosystem.

The Company views the launch of experiments at IQCC as an important first hardware milestone in this development effort. The initial stage does not constitute a demonstration of real-time quantum error correction or fault-tolerant quantum computation, both of which remain objectives of subsequent development phases.

About Quantum X Labs Inc.

Quantum X Labs Inc. and its subsidiaries are focused on quantum technology, digital advertising and computing and enterprise artificial intelligence (AI) solutions. Quantum X Labs Ltd. is focused on developing and promoting quantum algorithms for the transportation, drug discovery and security segments as well as developing quantum- based GPS replacement and quantum atom accuracy solutions. Gix Media develops a variety of technological software solutions, which perform automation, optimization and monetization of internet campaigns, for the purposes of acquiring and routing internet user traffic to its customers. Metagramm is a developer of grammatical error correction software and offers tools for writing and reviewing, grammar, spelling, punctuation and style features, as well as translation and multilingual dictionaries, using artificial intelligence and machine learning technology.

For more information about Quantum X Labs, visit https://quantumxlabs.xyz/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Quantum X Labs’ and its subsidiaries’ strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. For example, the Company is using forward-looking statements when it discusses the objectives, development roadmap, anticipated phases and potential benefits of its end-to-end quantum error correction program, the planned integration of its noise-aware decoder and accelerated decoding capabilities, the targeted closed-loop architecture, its anticipated collaboration with control-system and accelerated-computing partners, the role of quantum error correction in the industry, the Company’s strategic direction and technological roadmap, and the Company’s ability to translate its intellectual property and research programs into commercial products, governmental programs and revenue-generating opportunities . Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements, including, among others, the risk that experiments do not yield expected results, the Company’s continued access to third-party quantum hardware and facilities, its ability to enter into and maintain collaborations, its ability to obtain sufficient financing, technological developments by competitors, and its ability to protect its intellectual property. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s most recent Annual Report on Form 10-K and in subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Quantum X Labs is not responsible for the content of third-party websites.

Investor Relations Contacts:

Michal Efraty
Investor Relations
michal@efraty.com 

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) — Ponce Financial Group, Inc., (the “Company”) (Nasdaq: PDLB), the holding company for Ponce Bank, National Association (“Ponce Bank” or the “Bank”), today announced results for the third quarter of 2026.

Third Quarter 2026 Highlights (Compared to Prior Periods):

• Net income available to common stockholders was $18.0 million, or $0.76 per diluted share for the three months ended September 30, 2026, as compared to net income available to common stockholders of $8.2 million, or $0.35 per diluted share for the three months ended June 30, 2026 and net income available to common stockholders of $6.2 million, or $0.27 per diluted share for the three months ended September 30, 2025. Net income for the three months ended September 30, 2026 was $18.2 million. The Company paid dividends of $0.3 million on its preferred stock during the three months ended September 30, 2026.
• Included in the $18.0 million of net income available to common stockholders for the third quarter of 2026 results is $57.5 million in total interest and dividend income, $5.9 million in benefit for income taxes and $0.9 million in non-interest income, offset by $23.5 million in interest expense, $19.2 million in non-interest expense, $3.2 million in provision for credit losses and $0.3 million in dividends on preferred shares.
• The third quarter of 2026 results include certain unusual, non-recurring items. Specifically, the benefit for income taxes includes the release of the $10.5 million valuation allowance against the Company’s New York State and New York City deferred tax assets. The $1.2 million loss on real property included in non-interest income is due to the move of our Flushing property to held for sale. Non-interest income also includes a $0.4 million gain from the Company’s investment in Oaktree and Silvergate funds.
• Net interest income of $34.0 million for the third quarter of 2026 increased $3.9 million, or 13.07%, from the prior quarter and increased $8.7 million, or 34.62%, from the same quarter last year. Interest income for the quarter includes $0.8 million from a satisfied, former non-accrual loan. 
• Net interest margin was 3.86% for the third quarter of 2026, versus 3.66% for the prior quarter and 3.30% for the same quarter last year.

Nine Months 2026 Highlights (Compared to 2025)

• Net income available to common stockholders was $34.5 million, or $1.47 per diluted share for the nine months ended September 30, 2026, as compared to net income available to common stockholders of $17.7 million, or $0.77
  per diluted share for the nine months ended September 30, 2025. Net income for the nine months ended September 30, 2026 and 2025 was $35.4 million and $18.6 million, respectively. The Company paid dividends of $0.8 million on its preferred stock during both the nine months ended September 30, 2026 and 2025.
• Net interest income for the nine months ended September 30, 2026 was $92.3 million, an increase of $20.4 million, or 28.38%, compared to $71.9 million for the nine months ended September 30, 2025.
• Non-interest income for the nine months ended September 30, 2026 was $4.4 million, a decrease of $1.5 million, or 25.52%, from $5.9 million for the nine months ended September 30, 2025.
• Non-interest expense for the nine months ended September 30, 2026 was $54.6 million, an increase of $4.2 million, or 8.41%, compared to $50.4 million for the nine months ended September 30, 2025.
• Cash and equivalents were $132.2 million as of September 30, 2026, an increase of $6.1 million, or 4.80%, from $126.2 million as of December 31, 2025.
• Securities totaled $320.7 million as of September 30, 2026, a decrease of $44.5 million, or 12.19%, from $365.2 million as of December 31, 2025 primarily due to regular principal payments and the maturity of one available-for-sale security in the amount of $3.0 million.
• Net loans receivable were $3.08 billion as of September 30, 2026, an increase of $481.8 million, or 18.54%, from $2.60 billion as of December 31, 2025.
• Deposits were $2.37 billion as of September 30, 2026, an increase of $321.1 million, or 15.69%, from $2.05 billion as of December 31, 2025.

President and Chief Executive Officer’s Comments

Carlos P. Naudon, Ponce Financial Group, Inc.’s President and CEO, stated “Ponce continues to show strong results and deliver shareholder value. While the quarter includes some non-recurring items, our performance was robust even before accounting for those one-time events. Book value per share stands at $14.60, representing a $1.90 increase over the last twelve months. Furthermore, our net interest income continues to benefit from disciplined pricing and growth in earning assets, while non-performing assets decreased during the quarter to 50 basis points. Our capital position remains exceptionally strong and well in excess of regulatory requirements. We remain deeply committed to the communities we serve, and we will continue investing in both our people and technology to drive further operational efficiency.”

Executive Chairman’s Comment

Steven A. Tsavaris, Ponce Financial Group’s Executive Chairman added “We are pleased with our robust business activity during the quarter. As previously reported, we filed our second-quarter Quarterly Supplemental Report (QSR), which marks 16 consecutive quarters of deep impact lending above the 60% required threshold to repurchase our Preferred Stock. The U.S. Department of the Treasury has confirmed that the Company met this deep impact threshold. Consequently, we are actively collaborating with Treasury and its legal counsel to finalize the next steps for the Preferred Stock repurchase.”  

ECIP

The consummation of any such repurchase of our Preferred Stock is subject to the satisfaction of additional conditions, including satisfying certain eligibility criteria. Although the Company currently expects that it will satisfy all other necessary conditions, there can be no assurance if and when such repurchase will be consummated with Treasury.  

The table below indicates the Key Metrics at or for the three months ended:

	At or for the Three Months Ended
	September 30,				June 30,				March 31,				December 31,				September 30,
	2026				2026				2026				2025				2025
Performance Ratios:
Return on average assets (1)		1.99	%			1.00	%			1.07	%			1.26	%			0.82	%
Return on common equity (1)		20.18	%			9.81	%			10.37	%			12.50	%			8.10	%
Net interest margin (1) (2)		3.86	%			3.66	%			3.61	%			3.57	%			3.30	%
Non-interest expense to average assets (1)		2.13	%			2.14	%			2.14	%			2.06	%			2.10	%
Efficiency ratio (3)		55.21	%			57.41	%			56.96	%			52.95	%			62.15	%
Capital Ratios:
Total capital to risk-weighted assets (Ponce Financial Group)		18.66	%			20.00	%			21.23	%			23.00	%			24.08	%
Common equity Tier 1 capital to risk-weighted assets (Ponce Financial Group)		10.93	%			11.51	%			12.11	%			12.98	%			13.39	%
Tier 1 capital to total assets (Ponce Financial Group)		16.46	%			16.85	%			17.22	%			17.27	%			17.33	%
Total capital to risk-weighted assets (Bank only)		16.98	%			18.88	%			20.00	%			21.63	%			21.79	%
Common equity Tier 1 capital to risk-weighted assets (Bank only)		15.98	%			17.87	%			18.97	%			20.53	%			20.66	%
Tier 1 capital to total assets (Bank only)		14.85	%			15.81	%			16.09	%			16.12	%			16.08	%
Asset Quality Ratios:
Allowance for credit losses on loans as a percentage of total loans		0.94	%			0.95	%			0.96	%			0.97	%			0.98	%
Allowance for credit losses on loans as a percentage of nonperforming loans		156.85	%			116.91	%			128.93	%			94.74	%			88.88	%
Net (charge-offs) recoveries to average outstanding loans (1)		(0.05	%)			(0.05	%)			(0.08	%)			(0.13	%)			(0.03	%)
Non-performing assets as a percentage of total assets		0.50	%			0.67	%			0.62	%			0.83	%			0.88	%
Other:
Number of offices		17				17				17				17				18
Number of full-time equivalent employees		236				229				218				216				209

(1)	Annualized.
(2)	Net interest margin represents net interest income divided by average total interest-earning assets.
(3)	Efficiency ratio represents noninterest expense divided by the sum of net interest income and noninterest income.

Summary of Results of Operations

Net income for the three months ended September 30, 2026 was $18.2 million, increased $9.8 million, or 114.82%, compared to net income of $8.5 million for the three months ended June 30, 2026 and increased $11.7 million or 180.41% compared to net income of $6.5 million for the three months ended September 30, 2025.

The $9.8 million increase of net income for the three months ended September 30, 2026 compared to the three months ended June 30, 2026 was attributed mainly to an increase of $3.9 million in net interest income and $8.7 million in benefit for income taxes, offset by increases of $1.1 million in non-interest expense, $1.1 million in provision for credit losses and a decrease of $0.7 million in non-interest income.

The $11.7 million increase of net income for the three months ended September 30, 2026 compared to the three months ended September 30, 2025 was largely due to an increase of $8.7 million in net interest income and $8.1 million in benefit for income taxes, offset by increases of $2.6 million in non-interest expense and $1.9 million in provision for credit losses and a decrease of $0.6 million in non-interest income largely due to a $1.2 million loss on real property.

Net income for the nine months ended September 30, 2026 was $35.4 million, increased $16.8 million, or 90.48%, compared to net income of $18.6 million for the nine months ended September 30, 2025. The $16.8 million increase in net income was attributed mainly to an increase of $20.4 million in net interest income and $6.5 million in benefit for income taxes, offset by increases of $4.3 million in provision for credit losses and $4.2 million in non-interest expense and a decrease of $1.5 million in non-interest income largely due to a $1.2 million loss on real property.

Net Interest Income and Net Interest Margin

Net interest income for the three months ended September 30, 2026, increased $3.9 million, or 13.07%, to $34.0 million compared to $30.1 million for the three months ended June 30, 2026 and increased $8.7 million, or 34.62%, compared to $25.2 million for the three months ended September 30, 2025.

The $3.9 million increase in net interest income from the three months ended June 30, 2026 was attributable to an increase of $5.9 million in total interest and dividend income, offset by an increase of $1.9 million in total interest expense. The $8.7 million increase in net interest income from the three months ended September 30, 2025 was attributable to an increase of $10.7 million in total interest and dividend income, offset by an increase of $1.9 million in total interest expense.

Net interest income for the nine months ended September 30, 2026, increased $20.4 million, or 28.38%, to $92.3 million compared to $71.9 million for the nine months ended September 30, 2025. The $20.4 million increase in net interest income from the nine months ended September 30, 2025 was attributable to an increase of $21.1 million in total interest and dividend income, offset by an increase of $0.7 million in total interest expense.

Net interest margin was 3.86% for the three months ended September 30, 2026 compared to 3.66% for the prior quarter, an increase of 20bps and 3.30% for the same period last year, an increase of 56bps.

Net interest margin was 3.72% for the nine months ended September 30, 2026 compared to 3.18% for the nine months ended September 30, 2025, an increase of 54bps.

Non-interest Income

Non-interest income for the three months ended September 30, 2026, was $0.9 million, decreased $0.7 million, or 44.34%, compared to $1.5 million for the three months ended June 30, 2026, and decreased $0.6 million, or 43.03%, compared to $1.5 million for the three months ended September 30, 2025.

The $0.7 million decrease in non-interest income from the three months ended June 30, 2026 was largely attributable to a $1.2 million loss on real property, offset by an increase of $0.4 million in other non-interest income.

The $0.6 million decrease in non-interest income from the three months ended September 30, 2025 was largely attributable to a loss of $1.2 million on real property recognized in the third quarter of 2026, $0.4 million in grant income recognized in the third quarter of 2025 and a decrease of $0.2 million in late and prepayment charges, offset by an increase of $1.0 million in other non-interest income.

Non-interest income for the nine months ended September 30, 2026, was $4.4 million, a decrease of $1.5 million, or 25.52%, compared to $5.9 million for the nine months ended September 30, 2025. The $1.5 million decrease in non-interest income from the nine months ended September 30, 2025 was largely attributable to $1.2 million loss on real property, $0.8 million in grant income that was recognized during the nine months ended September 30, 2025, decreases of $0.5 million in late and prepayment charges and $0.4 million in income on sale of SBA loans, offset by increases of $1.3 million in other non-interest income and $0.2 million in service charges and fees.

Non-interest Expense

Non-interest expense for the three months ended September 30, 2026 was $19.2 million, increased $1.1 million, or 6.07%, compared to $18.1 million for the three months ended June 30, 2026 and increased $2.6 million, or 15.75%, compared to $16.6 million for the three months ended September 30, 2025.

The $1.1 million increase in non-interest expense from the three months ended June 30, 2026 was mainly attributable to an increase of $1.4 million in compensation and benefits as a result of new hires, partially offset by a decrease of $0.2 million in professional fees.

The $2.6 million increase in non-interest expense from the three months ended September 30, 2025 was mainly attributable to an increase of $2.6 million in compensation and benefits as a result of new hires.

Non-interest expense for the nine months ended September 30, 2026 was $54.6 million, increased $4.2 million, or 8.41%, compared to $50.4 million for the nine months ended September 30, 2025. The $4.2 million increase in non-interest expense from the nine months ended September 30, 2025 was mainly attributable to an increase of $5.0 million in compensation and benefits as a result of new hires, partially offset by decreases of $0.4 million in direct loan expenses, $0.3 million in occupancy and equipment and $0.1 million in other non-interest expense.

Credit Quality:

Total non-performing assets and accruing modifications to borrowers experiencing financial difficulty were $21.8 million at September 30, 2026 compared to $26.8 million at June 30, 2026 and $32.4 million at September 30, 2025.

During the three months ended September 30, 2026, a credit loss provision of $3.2 million on loans was recorded, consisting of $2.0 million charged on the funded portion and $1.2 million charged on the unfunded portion on loans. During the three months ended June 30, 2026, a credit loss provision of $2.1 million on loans was recorded, consisting of $1.7 million charged on the funded portion and $0.4 million charged on the unfunded portion on loans. During the three months ended September 30, 2025, a credit loss provision of $1.4 million on loans was recorded, consisting of $0.9 million charged on the funded portion on loans and $0.5 million charged on the unfunded portion on loans.

During the nine months ended September 30, 2026, a credit loss provision of $7.0 million on loans was recorded, consisting of $4.9 million charged on the funded portion and $2.1 million charged on the unfunded portion on loans. During the nine months ended September 30, 2025, a credit loss provision of $2.7 million on loans was recorded, consisting of $2.9 million charged on the funded portion on loans and a $0.2 million benefit on the unfunded portion on loans.

Balance Sheet Summary

Total assets increased $462.7 million, or 14.35%, to $3.69 billion as of September 30, 2026 from $3.22 billion as of December 31, 2025. The increase in total assets is largely attributable to increases of $481.8 million in net loans receivable, $14.3 million in deferred tax assets, $6.1 million in cash and cash equivalents, $4.8 million in Federal Home Loan Bank of New York stock, $3.7 million in accrued interest receivable and $2.2 million in other assets, partially offset by decreases of $31.8 million in held-to-maturity securities, $12.7 million in available-for-sale securities, $4.7 million in premises and equipment, net, and $1.3 million in right of use assets. The $4.7 million decrease in premises and equipment, net was largely attributable to $1.8 million of real property that was reclassified to held for sale and is reflected in other assets in the Consolidated Statements of Financial Condition and a $1.2 million loss on real property that is reflected in total non-interest income in the Consolidated Statements of Operations.

Total liabilities increased $426.0 million, or 15.88%, to $3.11 billion as of September 30, 2026 from $2.68 billion as of December 31, 2025. The increase in total liabilities was largely attributable to increases of $321.1 million in deposits, $100.0 million in borrowings and $6.0 million in other liabilities, partially offset by a decrease of $1.2 million in operating lease liabilities.

Total stockholders’ equity increased $36.7 million, or 6.78%, to $578.3 million as of September 30, 2026, from $541.5 million as of December 31, 2025. The $36.7 million increase in stockholders’ equity was largely attributable to $35.4 million in net income, $1.9 million impact to additional paid in capital as a result of share-based compensation, $1.9 million from release of ESOP shares and $0.2 million from exercise of stock options, offset by $1.8 million in other comprehensive loss and $0.8 million related to the dividend paid on preferred shares during the nine months ended September 30, 2026.

About Ponce Financial Group, Inc.

Ponce Financial Group, Inc. is the holding company for Ponce Bank, N.A. Ponce Bank, N.A. is a Minority Depository Institution, a Community Development Financial Institution, and a certified Small Business Administration lender. Ponce Bank, N.A.’s business primarily consists of taking deposits from the general public and to a lesser extent alternative funding sources and investing those funds, together with funds generated from operations and borrowings, in mortgage loans, consisting of 1-4 family residences (investor-owned and owner-occupied), multifamily residences, nonresidential properties, construction and land, and, to a lesser extent, in business and consumer loans. Ponce Bank, N.A. also invests in securities, which consist of U.S. Government and federal agency securities and securities issued by government-sponsored or government-owned enterprises, as well as, mortgage-backed securities, corporate bonds and obligations, Federal Home Loan Bank stock and Federal Reserve Bank stock.

Forward Looking Statements

Certain statements herein constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act and are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by words such as “believes,” “will,” “would,” “expects,” “project,” “may,” “could,” “developments,” “strategic,” “launching,” “opportunities,” “anticipates,” “estimates,” “intends,” “plans,” “targets” and similar expressions. These statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties. Actual results may differ materially from those set forth in the forward-looking statements as a result of numerous factors. Factors that could cause such differences to exist include, but are not limited to, adverse conditions in the capital and debt markets and the impact of such conditions on business activities; changes in interest rates; competitive pressures from other financial institutions; the effects of general economic conditions on a national basis or in the local markets in which Ponce Bank, N.A. operates, including changes that adversely affect borrowers’ ability to service and repay Ponce Bank, N.A.’s loans; changes in U.S. trade policies, including the imposition of tariffs and retaliatory tariffs, and their related impacts on the economy; changes in the global economy, including negative changes that may arise from armed conflict and geopolitical instability; changes in the value of securities in the investment portfolio; changes in loan default and charge-off rates; fluctuations in real estate values; the adequacy of loan loss reserves; decreases in deposit levels necessitating increased borrowing to fund loans and investments; operational risks including, but not limited to, cybersecurity, fraud and natural disasters; changes in government regulation; changes in accounting standards and practices; the risk that intangibles recorded in the financial statements will become impaired; demand for loans in Ponce Bank, N.A.’s market area; Ponce Bank, N.A.’s ability to attract and maintain deposits; risks related to the implementation of acquisitions, dispositions, and restructurings; the risk that Ponce Financial Group, Inc. may not be successful in the implementation of its business strategy; the risk that the repurchase of Ponce Financial Group, Inc.’s Preferred Stock issued under the ECIP may not be consummated on the anticipated timeline, on the anticipated terms, or at all; changes in assumptions used in making such forward-looking statements and the risk factors described in Ponce Financial Group, Inc.’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission (the “SEC”), which are available at the SEC’s website, www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Ponce Financial Group, Inc. disclaims any obligation to publicly update or revise any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes, except as may be required by applicable law or regulation.

Ponce Financial Group, Inc. and Subsidiaries Consolidated Statements of Financial Condition (Dollars in thousands, except for share data)
	As of
	September 30,				June 30,				March 31,				December 31,				September 30,
	2026				2026				2026				2025				2025
ASSETS
Cash and due from banks:
Cash	$	27,725			$	25,567			$	27,429			$	28,511			$	29,296
Interest-bearing deposits		104,486				114,443				89,817				97,643				117,283
Total cash and cash equivalents		132,211				140,010				117,246				126,154				146,579
Available-for-sale securities, at fair value		79,475				84,774				87,150				92,196				94,822
Held-to-maturity securities, at amortized cost		241,176				253,616				263,514				272,982				285,125
Placement with banks		249				249				249				249				249
Mortgage loans held for sale, at fair value		3,701				3,050				2,127				3,388				5,794
Loans receivable, net		3,081,101				2,879,740				2,698,649				2,599,258				2,490,046
Accrued interest receivable		21,624				19,939				19,274				17,905				18,903
Premises and equipment, net		10,924				14,645				15,159				15,638				16,129
Right of use assets		26,331				27,055				27,633				27,583				28,295
Federal Home Loan Bank of New York stock (FHLBNY), at cost		34,064				30,689				28,180				29,309				25,945
Federal Reserve Bank of New York stock (FRBNY), at cost		10,725				10,714				10,706				10,698				—
Deferred tax assets		25,770				12,979				11,729				11,501				12,402
Other assets		19,326				17,251				19,141				17,109				32,790
Total assets	$	3,686,677			$	3,494,711			$	3,300,757			$	3,223,970			$	3,157,079
LIABILITIES AND STOCKHOLDERS’ EQUITY
Liabilities:
Deposits	$	2,367,708			$	2,271,809			$	2,133,795			$	2,046,635			$	2,063,081
Borrowings		696,100				621,100				571,100				596,100				521,100
Operating lease liabilities		28,171				28,874				29,429				29,353				30,028
Accrued interest payable		3,862				3,837				4,338				3,788				4,372
Other liabilities		12,576				8,121				10,732				6,545				8,663
Total liabilities		3,108,417				2,933,741				2,749,394				2,682,421				2,627,244
Commitments and contingencies
Stockholders’ Equity:
Preferred stock, $0.01 par value; 100,000,000 shares authorized		225,000				225,000				225,000				225,000				225,000
Common stock, $0.01 par value; 200,000,000 shares authorized		249				249				249				249				249
Treasury stock, at cost		(5,738	)			(5,738	)			(5,738	)			(6,164	)			(7,270	)
Additional paid-in-capital		211,317				210,339				209,219				208,604				208,909
Retained earnings		169,855				151,887				143,674				135,332				125,477
Accumulated other comprehensive loss		(12,645	)			(10,698	)			(10,680	)			(10,820	)			(11,586	)
Unearned compensation ─ ESOP		(9,778	)			(10,069	)			(10,361	)			(10,652	)			(10,944	)
Total stockholders’ equity		578,260				560,970				551,363				541,549				529,835
Total liabilities and stockholders’ equity	$	3,686,677			$	3,494,711			$	3,300,757			$	3,223,970			$	3,157,079

Ponce Financial Group, Inc. and Subsidiaries Consolidated Statements of Operations (Dollars in thousands, except per share data)
	Three Months Ended
	September 30,				June 30,				March 31,				December 31,				September 30,
	2026				2026				2026				2025				2025
Interest and dividend income:
Interest on loans receivable	$	52,910			$	46,835			$	43,982			$	43,599			$	41,486
Interest on deposits due from banks		901				954				770				1,209				978
Interest and dividend on securities and FHLBNY stock		3,693				3,863				3,910				4,013				4,383
Total interest and dividend income		57,504				51,652				48,662				48,821				46,847
Interest expense:
Interest on certificates of deposit		7,313				6,785				6,415				6,706				6,553
Interest on other deposits		10,430				9,544				8,630				9,106				9,996
Interest on borrowings		5,772				5,262				5,391				5,075				5,050
Total interest expense		23,515				21,591				20,436				20,887				21,599
Net interest income		33,989				30,061				28,226				27,934				25,248
Provision for credit losses		3,219				2,148				1,656				1,078				1,364
Net interest income after provision for credit losses		30,770				27,913				26,570				26,856				23,884
Non-interest income:
Service charges and fees		611				600				539				542				539
Brokerage commissions		—				—				—				23				8
Late and prepayment charges		232				138				726				1,173				385
Income on sale of mortgage loans		188				161				120				139				166
Grant income		—				—				—				428				429
Loss on real property		(1,166	)			—				—				—				—
Other		985				628				657				1,174				(35	)
Total non-interest income		850				1,527				2,042				3,479				1,492
Non-interest expense:
Compensation and benefits		10,509				9,070				8,663				8,113				7,868
Occupancy and equipment		3,879				3,901				3,672				4,033				3,934
Data processing expenses		1,202				1,195				1,219				1,223				1,296
Direct loan expenses		89				187				121				116				155
Insurance and surety bond premiums		332				332				333				324				318
Office supplies, telephone and postage		147				152				193				186				170
Professional fees		1,305				1,470				1,346				1,392				1,409
Marketing and promotional expenses		144				190				228				94				184
Federal deposit insurance and regulatory assessment		495				408				409				97				266
Other operating expenses		1,134				1,230				1,056				1,056				1,018
Total non-interest expense		19,236				18,135				17,240				16,634				16,618
Income before income taxes		12,384				11,305				11,372				13,701				8,758
(Benefit) provision for income taxes		(5,865	)			2,810				2,749				3,565				2,250
Net income	$	18,249			$	8,495			$	8,623			$	10,136			$	6,508
Dividends on preferred shares		281				282				281				281				281
Net income available to common stockholders	$	17,968			$	8,213			$	8,342			$	9,855			$	6,227
Earnings per common share:
Basic	$	0.78			$	0.36			$	0.36			$	0.43			$	0.27
Diluted	$	0.76			$	0.35			$	0.36			$	0.42			$	0.27
Weighted average common shares outstanding:
Basic		23,086,892				23,053,460				22,988,317				22,837,044				22,766,195
Diluted		23,650,370				23,508,153				23,331,314				23,263,708				23,135,448

Ponce Financial Group, Inc. and Subsidiaries Consolidated Statements of Operations (Dollars in thousands, except per share data)
		For the Nine Months Ended September 30,
		2026				2025				Variance $				Variance %
Interest and dividend income:
Interest on loans receivable		$	143,727			$	118,913			$	24,814				20.87	%
Interest on deposits due from banks			2,625				3,453				(828	)			(23.98	%)
Interest and dividend on securities and FHLBNY stock			11,466				14,338				(2,872	)			(20.03	%)
Total interest and dividend income			157,818				136,704				21,114				15.45	%
Interest expense:
Interest on certificates of deposit			20,513				21,689				(1,176	)			(5.42	%)
Interest on other deposits			28,604				27,608				996				3.61	%
Interest on borrowings			16,425				15,530				895				5.76	%
Total interest expense			65,542				64,827				715				1.10	%
Net interest income			92,276				71,877				20,399				28.38	%
Provision for credit losses			7,023				2,705				4,318				159.63	%
Net interest income after provision for credit losses			85,253				69,172				16,081				23.25	%
Non-interest income:
Service charges and fees			1,750				1,575				175				11.11	%
Brokerage commissions			—				12				(12	)			(100.00	%)
Late and prepayment charges			1,096				1,612				(516	)			(32.01	%)
Income on sale of mortgage loans			469				483				(14	)			(2.90	%)
Income on sale of SBA loans			—				404				(404	)			(100.00	%)
Grant income			—				857				(857	)			(100.00	%)
Loss on real property			(1,166	)			—				(1,166	)			—	%
Other			2,270				990				1,280				129.29	%
Total non-interest income			4,419				5,933				(1,514	)			(25.52	%)
Non-interest expense:
Compensation and benefits			28,242				23,275				4,967				21.34	%
Occupancy and equipment			11,452				11,754				(302	)			(2.57	%)
Data processing expenses			3,616				3,636				(20	)			(0.55	%)
Direct loan expenses			397				784				(387	)			(49.36	%)
Insurance and surety bond premiums			997				930				67				7.20	%
Office supplies, telephone and postage			492				514				(22	)			(4.28	%)
Professional fees			4,121				4,140				(19	)			(0.46	%)
Marketing and promotional expenses			562				533				29				5.44	%
Federal deposit insurance and regulatory assessments			1,312				1,273				39				3.06	%
Other operating expenses			3,420				3,536				(116	)			(3.28	%)
Total non-interest expense			54,611				50,375				4,236				8.41	%
Income before income taxes			35,061				24,730				10,331				41.78	%
(Benefit) provision for income taxes			(306	)			6,163				(6,469	)			(104.97	%)
Net income		$	35,367			$	18,567			$	16,800				90.48	%
Dividends on preferred shares			844				844				—				—	%
Net income available to common stockholders		$	34,523			$	17,723			$	16,800				94.79	%
Earnings per common share:
Basic		$	1.50			$	0.78			$	0.72				92.31	%
Diluted		$	1.47			$	0.77			$	0.70				90.91	%
Weighted average common shares outstanding:
Basic			23,043,250				22,715,620				327,630				1.44	%
Diluted			23,496,728				22,992,655				504,073				2.19	%

Ponce Financial Group, Inc. and Subsidiaries Loans Receivable excluding Mortgage Loans Held for Sale
		As of
		September 30,								June 30,								March 31,								December 31,								September 30,
		2026								2026								2026								2025								2025
		Amount				Percent				Amount				Percent				Amount				Percent				Amount				Percent				Amount				Percent
		(Dollars in thousands)
Mortgage loans:
1-4 family residential		$	413,064				13.26	%		$	426,343				14.65	%		$	431,377				15.82	%		$	434,374				16.54	%		$	444,602				17.67	%
Multifamily residential			1,051,642				33.76	%			1,057,612				36.35	%			915,333				33.58	%			756,542				28.83	%			688,574				27.39	%
Nonresidential properties			557,449				17.89	%			535,521				18.41	%			534,256				19.60	%			526,210				20.05	%			436,175				17.35	%
Construction and land			1,016,809				32.64	%			817,151				28.08	%			763,990				28.03	%			854,096				32.54	%			886,369				35.25	%
Total mortgage loans			3,038,964				97.55	%			2,836,627				97.49	%			2,644,956				97.03	%			2,571,222				97.96	%			2,455,720				97.66	%
Non-mortgage loans:
Business loans			75,852				2.43	%			72,438				2.49	%			80,366				2.95	%			53,063				2.02	%			58,012				2.31	%
Consumer loans			581				0.02	%			577				0.02	%			596				0.02	%			625				0.02	%			727				0.03	%
Total non-mortgage loans			76,433				2.45	%			73,015				2.51	%			80,962				2.97	%			53,688				2.04	%			58,739				2.34	%
Total loans, gross			3,115,397				100.00	%			2,909,642				100.00	%			2,725,918				100.00	%			2,624,910				100.00	%			2,514,459				100.00	%
Net deferred loan origination fees			(5,128	)							(2,348	)							(1,031	)							(203	)							351
Allowance for credit losses on loans			(29,168	)							(27,554	)							(26,238	)							(25,449	)							(24,764	)
Loans, net		$	3,081,101							$	2,879,740							$	2,698,649							$	2,599,258							$	2,490,046

Ponce Financial Group, Inc. and Subsidiaries Allowance for Credit Losses on Loans
	For the Three Months Ended
	September 30,				June 30,				March 31,				December 31,				September 30,
	2026				2026				2026				2025				2025
	(Dollars in thousands)
Allowance for credit losses on loans at beginning of the period	$	27,554			$	26,238			$	25,449			$	24,764			$	24,100
Provision for credit losses on loans		1,996				1,669				1,293				1,526				864
Charge-offs:
Mortgage loans:
1-4 family residential		(5	)			—				—				(32	)			—
Multifamily residences		(65	)			—				—				—				—
Non-mortgage loans:
Business		(317	)			(354	)			(504	)			(801	)			(200	)
Consumer		—				—				—				(44	)			—
Total charge-offs		(387	)			(354	)			(504	)			(877	)			(200	)
Recoveries:
Mortgage loans:
1-4 family residential		—				1				—				1				—
Non-mortgage loans:
Business		5				—				—				35				—
Total recoveries		5				1				—				36				—
Net (charge-offs) recoveries		(382	)			(353	)			(504	)			(841	)			(200	)
Allowance for credit losses on loans at end of the period	$	29,168			$	27,554			$	26,238			$	25,449			$	24,764

Ponce Financial Group, Inc. and Subsidiaries Deposits
		As of
		September 30,								June 30,								March 31,								December 31,								September 30,
		2026								2026								2026								2025								2025
		Amount				Percent				Amount				Percent				Amount				Percent				Amount				Percent				Amount				Percent
		(Dollars in thousands)
Demand		$	244,860				10.34	%		$	251,919				11.10	%		$	241,012				11.29	%		$	208,250				10.18	%		$	192,595				9.34	%
Interest-bearing deposits:
NOW/IOLA accounts			76,392				3.23	%			71,987				3.17	%			78,192				3.66	%			84,012				4.10	%			75,051				3.64	%
Money market accounts			898,719				37.96	%			929,002				40.89	%			811,982				38.05	%			779,532				38.09	%			821,844				39.84	%
Reciprocal deposits			188,016				7.94	%			164,883				7.26	%			162,926				7.64	%			152,630				7.46	%			154,548				7.49	%
Savings accounts			118,727				5.01	%			115,233				5.07	%			118,373				5.55	%			117,708				5.75	%			117,401				5.69	%
Total NOW, money market, reciprocal and savings accounts			1,281,854				54.14	%			1,281,105				56.39	%			1,171,473				54.90	%			1,133,882				55.40	%			1,168,844				56.66	%
Certificates of deposit of $250K or more			202,702				8.56	%			194,462				8.56	%			258,093				12.10	%			202,500				9.89	%			209,819				10.17	%
Brokered certificates of deposit (1)			144,569				6.11	%			94,557				4.16	%			54,553				2.56	%			67,942				3.32	%			67,952				3.29	%
Listing service deposits (1)			994				0.04	%			994				0.04	%			1,243				0.06	%			4,150				0.20	%			4,150				0.20	%
All other certificates of deposit less than $250K			492,729				20.81	%			448,772				19.75	%			407,421				19.09	%			429,911				21.01	%			419,721				20.34	%
Total certificates of deposit			840,994				35.52	%			738,785				32.51	%			721,310				33.81	%			704,503				34.42	%			701,642				34.00	%
Total interest-bearing deposits			2,122,848				89.66	%			2,019,890				88.90	%			1,892,783				88.71	%			1,838,385				89.82	%			1,870,486				90.66	%
Total deposits		$	2,367,708				100.00	%		$	2,271,809				100.00	%		$	2,133,795				100.00	%		$	2,046,635				100.00	%		$	2,063,081				100.00	%

(1)	At September 30, 2026, June 30, 2026, March 31, 2026, December 31, 2025 and September 30, 2025, there were no individual listing service deposits amounting to $250,000 or more, and no individual brokered certificates of deposits amounting to $250,000 or more.

Ponce Financial Group, Inc. and Subsidiaries Nonperforming Assets
	As of
	September 30,				June 30,				March 31,				December 31,				September 30,
	2026				2026				2026				2025				2025
	(Dollars in thousands)
Non-accrual loans:
Mortgage loans:
1-4 family residential	$	2,767			$	5,843			$	3,158			$	4,427			$	3,176
Multifamily residential		11,100				12,133				9,228				13,112				14,202
Nonresidential properties		—				—				—				—				—
Construction and land		4,100				5,040				7,061				8,247				8,907
Non-mortgage loans:
Business		146				77				427				667				880
Consumer		—				—				—				—				—
Total non-accrual loans (not including non-accruing modifications to borrowers experiencing financial difficulty) (1)	$	18,113			$	23,093			$	19,874			$	26,453			$	27,165
Non-accruing modifications to borrowers experiencing financial difficulty (1):
Mortgage loans:
1-4 family residential		483				475				477				410				698
Total non-accruing modifications to borrowers experiencing financial difficulty (1)		483				475				477				410				698
Total non-performing assets (2)	$	18,596			$	23,568			$	20,351			$	26,863			$	27,863
Accruing modifications to borrowers experiencing financial difficulty (1):
Mortgage loans:
1-4 family residential		2,431				2,456				2,481				2,574				3,725
Nonresidential properties		598				618				613				621				629
Non-mortgage loans:
Business		168				175				185				190				196
Total accruing modifications to borrowers experiencing financial difficulty (1)	$	3,197			$	3,249			$	3,279			$	3,385			$	4,550
Total non-performing assets and accruing modifications to borrowers experiencing financial difficulty (1)	$	21,793			$	26,817			$	23,630			$	30,248			$	32,413
Total non-performing assets to total assets		0.50	%			0.67	%			0.62	%			0.83	%			0.88	%

(1)	Balances include both modifications to borrowers experiencing financial difficulty, in accordance with ASU 2022-02 adopted on January 1, 2023, and previously existing troubled debt restructurings.
(2)	Includes nonperforming mortgage loans held for sale.

Ponce Financial Group, Inc. and Subsidiaries Average Balance Sheets
	For the Three Months Ended September 30,
	2026											2025
	Average											Average
	Outstanding								Average			Outstanding								Average
	Balance				Interest				Yield/Rate (1)			Balance				Interest				Yield/Rate (1)
	(Dollars in thousands)
Interest-earning assets:
Loans (2)	$	3,025,085			$	52,910			6.94	%		$	2,499,268			$	41,486			6.59	%
Securities (3)		332,919				3,067			3.65	%			418,513				3,913			3.71	%
Other (4)		133,827				1,527			4.53	%			119,262				1,448			4.82	%
Total interest-earning assets		3,491,831				57,504			6.53	%			3,037,043				46,847			6.12	%
Non-interest-earning assets		97,667											96,095
Total assets	$	3,589,498										$	3,133,138
Interest-bearing liabilities:
NOW/IOLA	$	76,801			$	145			0.75	%		$	78,526			$	137			0.69	%
Money market		1,109,784				10,254			3.67	%			958,277				9,831			4.07	%
Savings		119,109				31			0.10	%			119,159				28			0.09	%
Certificates of deposit		794,477				7,313			3.65	%			698,019				6,553			3.72	%
Total deposits		2,100,171				17,743			3.35	%			1,853,981				16,549			3.54	%
Borrowings		624,361				5,772			3.67	%			521,100				5,050			3.84	%
Total interest-bearing liabilities		2,724,532				23,515			3.42	%			2,375,081				21,599			3.61	%
Non-interest-bearing liabilities:
Non-interest-bearing demand		251,823				—							199,922				—
Other non-interest-bearing liabilities		43,730				—							31,406				—
Total non-interest-bearing liabilities		295,553				—							231,328				—
Total liabilities		3,020,085				23,515							2,606,409				21,599
Total equity		569,413											526,729
Total liabilities and total equity	$	3,589,498							3.42	%		$	3,133,138							3.61	%
Net interest income					$	33,989										$	25,248
Net interest rate spread (5)									3.11	%										2.51	%
Net interest-earning assets (6)	$	767,299										$	661,962
Net interest margin (7)									3.86	%										3.30	%
Average interest-earning assets to interest-bearing liabilities									128.16	%										127.87	%

(1)	Annualized where appropriate.
(2)	Loans include loans and mortgage loans held for sale, at fair value.
(3)	Securities include available-for-sale securities and held-to-maturity securities.
(4)	Includes FHLBNY demand account, FHLBNY stock dividends and FRBNY demand deposits.
(5)	Net interest rate spread represents the difference between the weighted average yield on interest-earning assets and the weighted average rate of interest-bearing liabilities.
(6)	Net interest-earning assets represent total interest-earning assets less total interest-bearing liabilities.
(7)	Net interest margin represents net interest income divided by average total interest-earning assets.

Ponce Financial Group, Inc. and Subsidiaries Average Balance Sheets
	For the Nine Months Ended September 30,
	2026												2025
	Average												Average
	Outstanding								Average				Outstanding								Average
	Balance				Interest				Yield/Rate (1)				Balance				Interest				Yield/Rate (1)
	(Dollars in thousands)
Interest-earning assets:
Loans (2)	$	2,836,725			$	143,727				6.77	%		$	2,439,280			$	118,913				6.52	%
Securities (3)		346,223				9,474				3.66	%			445,130				12,680				3.81	%
Other (4)		136,792				4,617				4.51	%			135,600				5,111				5.04	%
Total interest-earning assets		3,319,740				157,818				6.36	%			3,020,010				136,704				6.05	%
Non-interest-earning assets		96,477												103,059
Total assets	$	3,416,217											$	3,123,069
Interest-bearing liabilities:
NOW/IOLA	$	76,737			$	397				0.69	%		$	73,034			$	352				0.64	%
Money market		1,029,534				28,120				3.65	%			884,115				27,172				4.11	%
Savings		120,029				87				0.10	%			118,656				84				0.09	%
Certificates of deposit		752,638				20,513				3.64	%			754,531				21,689				3.84	%
Total deposits		1,978,938				49,117				3.32	%			1,830,336				49,297				3.60	%
Borrowings		594,800				16,425				3.69	%			536,851				15,530				3.87	%
Total interest-bearing liabilities		2,573,738				65,542				3.40	%			2,367,187				64,827				3.66	%
Non-interest-bearing liabilities:
Non-interest-bearing demand		239,239				—								199,978				—
Other non-interest-bearing liabilities		44,440				—								37,206				—
Total non-interest-bearing liabilities		283,679				—								237,184				—
Total liabilities		2,857,417				65,542								2,604,371				64,827
Total equity		558,800												518,698
Total liabilities and total equity	$	3,416,217								3.40	%		$	3,123,069								3.66	%
Net interest income					$	92,276											$	71,877
Net interest rate spread (5)										2.96	%											2.39	%
Net interest-earning assets (6)	$	746,002											$	652,823
Net interest margin (7)										3.72	%											3.18	%
Average interest-earning assets to
interest-bearing liabilities										128.99	%											127.58	%

(1)	Annualized where appropriate.
(2)	Loans include loans and mortgage loans held for sale, at fair value.
(3)	Securities include available-for-sale securities and held-to-maturity securities.
(4)	Includes FHLBNY demand account, FHLBNY stock dividends and FRBNY demand deposits.
(5)	Net interest rate spread represents the difference between the weighted average yield on interest-earning assets and the weighted average rate of interest-bearing liabilities.
(6)	Net interest-earning assets represent total interest-earning assets less total interest-bearing liabilities.
(7)	Net interest margin represents net interest income divided by average total interest-earning assets.

Ponce Financial Group, Inc. and Subsidiaries Other Data
	As of
	September 30,				June 30,				March 31,				December 31,				September 30,
	2026				2026				2026				2025				2025
Other Data
Common shares issued		24,886,711				24,886,711				24,886,711				24,886,711				24,886,711
Less treasury shares		698,810				698,810				698,810				750,785				885,586
Common shares outstanding at end of period		24,187,901				24,187,901				24,187,901				24,135,926				24,001,125
Book value per common share	$	14.60			$	13.89			$	13.49			$	13.12			$	12.70
Tangible book value per common share (1)	$	14.60			$	13.89			$	13.49			$	13.12			$	12.70

(1)

Tangible book value per common share is a non-GAAP financial measure and is calculated by dividing tangible common equity by common shares outstanding. Tangible common equity is defined as total common shareholders’ equity less goodwill and other intangible assets, net of applicable deferred taxes. The Company believes that tangible book value per common share is a useful measure for investors, regulators, and analysts because it reflects the Company’s capital position excluding the impact of goodwill and other intangible assets, which may not be realizable in a liquidation scenario. This measure is commonly used in the banking industry to assess financial condition and capital adequacy. Tangible book value per common share should not be considered a substitute for book value per common share, which is calculated in accordance with GAAP, and the Company’s definition of tangible book value per common share may differ from similarly titled measures used by other companies. During the periods presented, the Company did not make any adjustments for goodwill and other intangible assets, so tangible book value per common share is equal to the book value per common share as calculated in accordance with GAAP.

Contact:
Sergio J. Vaccaro
sergio.vaccaro@poncebank.net
718-931-9000